TARA PETERSON: Open Payments
NPI 1235108457 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$420 in 22 payments from 10 companies in 2025. Trend: 2023 $454 · 2024 $616 · 2025 $420
Food & beverage: $420
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 4 | $78 |
| Madrigal Pharmaceuticals | 3 | $61 |
| ABBVIE INC. | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $43 |
| GENZYME CORPORATION | 1 | $35 |
| Phathom Pharmaceuticals, Inc. | 4 | $33 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| PFIZER INC. | 1 | $16 |
Products named: TREMFYA, REZDIFFRA, XIFAXAN, DUPIXENT, VOQUEZNA, GATTEX, ZENPEP, RINVOQ.
Industry payments across NE — which companies pay providers there.
